Univest
Univest
  • Markets

Astrazeneca Pharma India Ltd. (ASTRAZEN) 52 Week Low Streak: Second Straight Session, Rs 2.19% Drop

  • September 2, 2026
  • Posted by: Kunal Singla
  • Category: News
No Comments
Astrazeneca Pharma India Ltd. 52 Week Low Streak
Astrazeneca Pharma India Ltd. (ASTRAZEN) share price fell to a fresh 52-week low of Rs 6,084.05 today and later stood at Rs 6,117.55, down 1.15% from the previous close. Market cap was Rs 15,471.88 crore.

Astrazeneca Pharma India Ltd. has now set a fresh 52-week low for its second straight session, extending a decline of 2.19% across the streak to a latest trough of Rs 6,084.05. The stock closed at Rs 6,117.55, and Univest data confirms the repeated-low pattern but does not establish a company-specific cause for the continued move. For readers tracking Astrazeneca Pharma India Ltd. 52 Week Low Streak, the key point is the persistence of the breakdown rather than just the latest daily move.

With a market capitalisation of Rs 15,471.88 crore, Astrazeneca Pharma India Ltd. remains a sizeable healthcare company even as the repeated-low pattern keeps the share price under pressure. A second straight fresh yearly low is more informative than a single-day break because it shows the decline has carried forward into another session. For investors, Astrazeneca Pharma India Ltd. 52 Week Low Streak is therefore a signal to watch the depth and continuity of the move, not to treat it as an isolated price event.

Table of Contents

Toggle
  • Astrazeneca Pharma India Ltd. 52 Week Low Streak: Consecutive Low Analysis
  • What the Repeated 52-Week Lows Show
  • Astrazeneca Pharma India Ltd. (ASTRAZEN) Fundamental Analysis
  • Sector and Industry Context
  • Peer Comparison
  • Why Investors Are Watching
  • About the Company
  • Track Astrazeneca Pharma India Ltd. Share Price on Univest
  • Frequently Asked Questions
    • What does Astrazeneca Pharma India Ltd. 52 Week Low Streak mean?
    • How many sessions has Astrazeneca Pharma India Ltd. set a fresh 52-week low?
    • What is the latest 52-week low for Astrazeneca Pharma India Ltd.?
    • How does Astrazeneca Pharma India Ltd. look on valuation after the streak?
    • How does the company compare with the healthcare sector?
    • Why is the repeated 52-week low more important than a single-day dip?
    • What should investors monitor next?

Astrazeneca Pharma India Ltd. 52 Week Low Streak: Consecutive Low Analysis

Metric Value
Current Price Rs 6,117.55
Previous Close Rs 6,188.75
Today's Move Rs -71.2 (-1.15%)
Open Rs 6,133
High Rs 6,154.05
Low Rs 6,084.05
Market Capitalisation Rs 15,471.88 crore

Astrazeneca Pharma India Ltd. (ASTRAZEN) traded at Rs 6,117.55 versus the previous close of Rs 6,188.75, a fall of 1.15%. The stock opened at Rs 6,133, reached a high of Rs 6,154.05, touched a low of Rs 6,084.05.

Astrazeneca Pharma India Ltd. 52 Week Low Streak extended through another weak session, with the stock ending at Rs 6,117.55 against the previous close of Rs 6,188.75. That left the share price down Rs 71.20, or 1.15%, on the day. The open at Rs 6,133.00 was below the prior close, and the stock moved between Rs 6,154.05 and Rs 6,084.05 during the session, finishing near the lower end of that range. The close at Rs 6,117.55 sat just above the intraday low, which kept Astrazeneca Pharma India Ltd. 52 Week Low Streak in focus for market participants watching the latest yearly low.

The session matters because it shows Astrazeneca Pharma India Ltd. 52 Week Low Streak was not limited to a single intraday dip. The day’s low matched the fresh 52-week trough, while the close remained only modestly above it. Market capitalisation stood at Rs 15,471.88 crore, giving context to the decline in a stock that still sits within a large listed healthcare business. For readers, Astrazeneca Pharma India Ltd. 52 Week Low Streak is best read as a continued downward reset in price rather than a one-off slip.

What the Repeated 52-Week Lows Show

Astrazeneca Pharma India Ltd. 52 Week Low Streak now reflects two consecutive sessions of fresh one-year lows, which makes the pattern more important than the latest close alone. The first breakdown on 30 September 2026 is now followed by another lower finish, and the cumulative decline across the streak has reached 2.19%. That cumulative move is the central number for Astrazeneca Pharma India Ltd. 52 Week Low Streak because it captures the full run, not just the final daily change.

The current low of Rs 6,084.05 is the new reference point for the market. Because Univest data does not supply a previous 52-week low beyond the current trough, Astrazeneca Pharma India Ltd. 52 Week Low Streak should be read using the observed streak itself rather than a comparison with an earlier low level. The latest Univest data confirms the repeated yearly-low pattern, but it does not confirm a company-specific reason. In practical terms, Astrazeneca Pharma India Ltd. 52 Week Low Streak tells readers that the downside has persisted into a second session and that the market is still repricing the stock lower.

Astrazeneca Pharma India Ltd. (ASTRAZEN) Fundamental Analysis

Metric Value
Market Capitalisation Rs 15,471.88 crore
P/E Ratio 91.21x
P/B Ratio 17.11x
ROE 23.02%
ROCE 31.24%
EPS Rs 67.85
Book Value Per Share Rs 361.68
Dividend Yield 0.58%

Astrazeneca Pharma India Ltd. (ASTRAZEN) fundamental metrics show P/E 91.21x, P/B 17.11x, ROE 23.02%, ROCE 31.24%. These ratios show where the company stands today and are not a call to buy or sell.

Astrazeneca Pharma India Ltd. has a market capitalisation of Rs 15,471.88 crore, which gives readers a sense of company size before judging valuation. On valuation, P/E at 91.21x, P/B at 17.11x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 23.02% and ROCE of 31.24%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 67.85, book value per share of Rs 361.68, dividend yield of 0.58%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 32.01x, median ROE of 11.7%, median ROCE of 13.46%. Together they describe the fundamental backdrop without implying a buy or sell view.

Sector and Industry Context

Metric Value
Sector Healthcare
Industry Pharmaceuticals & Drugs
Benchmark Scope same industry
Company P/E Ratio 91.21x
Benchmark Median P/E 32.01x
Benchmark Average P/E 48.92x
Benchmark P/E Range 3.4x to 688.17x
Company P/B Ratio 17.11x
Benchmark Median P/B 2.92x
Company ROE 23.02%
Benchmark Median ROE 11.7%
Company ROCE 31.24%
Benchmark Median ROCE 13.46%
Company Market Capitalisation Rs 15,471.88 crore
Benchmark Median Market Cap Rs 765.11 crore

Astrazeneca Pharma India Ltd. (ASTRAZEN) operates in the Healthcare sector, within the Pharmaceuticals & Drugs industry.

Astrazeneca Pharma India Ltd. (ASTRAZEN) has a P/E ratio of 91.21x, which is above the benchmark median of 32.01x, a difference of +184.94%. A P/E difference of this kind is a reference point rather than a recommendation.

Astrazeneca Pharma India Ltd. (ASTRAZEN) has a ROE of 23.02%, which is above the benchmark median of 11.7%, a difference of +96.75%. Astrazeneca Pharma India Ltd. (ASTRAZEN) has a ROCE of 31.24%, which is above the benchmark median of 13.46%, a difference of +132.1%.

Track stocks falling to yearly lows through the Univest 52-week-low screener. The peer table below provides the company-level comparison.

Peer Comparison

Company Symbol Market Cap (Cr) P/E P/B ROE (%) ROCE (%)
Marksans Pharma Ltd. MARKSANS 15,534.45 28.26 4.59 15.31 21.1
Natco Pharma Ltd. NATCOPHARM 15,115.98 12.94 1.59 16.3 17.16
Concord Biotech Ltd. CONCORDBIO 14,750.36 52.18 6.93 13.54 18.04
Jubilant Pharmova Ltd. JUBLPHARMA 16,719.74 46.54 2.3 5.97 8.69
Eris Lifesciences Ltd. ERIS 16,904.6 25.64 4.09 19.23 14.47

Astrazeneca Pharma India Ltd. (ASTRAZEN) has a P/E ratio of 91.21x compared with the displayed peer median of 28.26x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 23.02% compares with a peer median of 15.31% across the companies shown in the table. ROCE stood at 31.24% versus the displayed peer median of 17.16%, providing a capital-efficiency comparison. Astrazeneca Pharma India Ltd. (ASTRAZEN) has a market capitalisation of Rs 15,471.88 crore. Among the 5 peers shown, 3 have a larger market capitalisation.

Why Investors Are Watching

  • Astrazeneca Pharma India Ltd. 52 Week Low Streak has now run for two consecutive sessions, which makes the pattern more meaningful than a single-day break.
  • The cumulative decline across Astrazeneca Pharma India Ltd. 52 Week Low Streak is 2.19%, giving a clearer view of the full move.
  • The latest low of Rs 6,084.05 is the new reference point for traders and long-term readers watching Astrazeneca Pharma India Ltd. 52 Week Low Streak.
  • Valuation remains elevated at 91.21 times earnings and 17.11 times book, even after Astrazeneca Pharma India Ltd. 52 Week Low Streak.
  • The stock still compares differently from peers and sector medians, so Astrazeneca Pharma India Ltd. 52 Week Low Streak remains a valuation story as much as a price story.

About the Company

Astrazeneca Pharma India Ltd. operates in Pharmaceuticals & Drugs within the Healthcare sector. For readers tracking Astrazeneca Pharma India Ltd. 52 Week Low Streak, the relevant business context is its position as a listed pharmaceutical company with a sizeable market capitalisation and a premium valuation profile. The company’s reported ROE, ROCE, EPS and book value show that the business remains established, even though the share price has moved to a fresh 52-week low again.

That context matters because Astrazeneca Pharma India Ltd. 52 Week Low Streak should not be read as a question about business existence or scale. It is a question about how the market is pricing a healthcare company whose current multiples remain above peers and industry medians. The article therefore focuses on the streak, the valuation and the sector position rather than a generic company profile.

Track Astrazeneca Pharma India Ltd. Share Price on Univest

Use Astrazeneca Pharma India Ltd. (ASTRAZEN) live share-price page, Univest 52-week-low screener, Univest market blogs to review live stock data, yearly-low lists and related market analysis.

Astrazeneca Pharma India Ltd. 52 Week Low Streak is best followed alongside the next close, because consecutive lows can change the market’s reference point quickly. Readers tracking Astrazeneca Pharma India Ltd. 52 Week Low Streak can monitor the share price, valuation ratios and sector comparison on the company’s stock page to see whether the price keeps printing lower yearly levels or stabilises around the current trough.

The most useful watchlist for Astrazeneca Pharma India Ltd. 52 Week Low Streak is simple: the latest close, the next 52-week low reference and the way the valuation compares with the same industry and peer set. Those are the variables that shape the streak story.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Uniresearch Global Pvt. Ltd. (Research Analyst, SEBI Reg. No. INH000013776, a subsidiary of Univest Communication Technologies Private Limited).

Frequently Asked Questions

What does Astrazeneca Pharma India Ltd. 52 Week Low Streak mean?

Ans. It means Astrazeneca Pharma India Ltd. has set a fresh 52-week low in consecutive sessions. In this case, the streak has reached a second straight session, which makes the decline more notable than a one-day move.

How many sessions has Astrazeneca Pharma India Ltd. set a fresh 52-week low?

Ans. The stock has set a fresh 52-week low for two consecutive sessions.The stock moved -1.15% during the session.

What is the latest 52-week low for Astrazeneca Pharma India Ltd.?

Ans.05. That level was also the day’s low in the most recent session, which keeps the streak active. The stock moved -1.15% during the session.

How does Astrazeneca Pharma India Ltd. look on valuation after the streak?

Ans. The stock trades at 91.21 times earnings and 17.11 times book.The company trades at a P/E ratio of 91.21x.

How does the company compare with the healthcare sector?

Ans. Its P/E and P/B are well above the sector medians, while ROE and ROCE are also stronger than the industry medians. That means the stock is still priced at a premium relative to the sector.

Why is the repeated 52-week low more important than a single-day dip?

Ans. Two consecutive lows show that the weakness carried forward into another session. That makes Astrazeneca Pharma India Ltd. 52 Week Low Streak more informative than a one-day break in isolation.

What should investors monitor next?

Ans. Investors should watch whether the stock trades below the current low again, how the close behaves near Rs 6,084.05, and whether valuation multiples continue to compress as the streak develops.



Author: Kunal Singla
Kunal Singla is the Associate Director - Research at Univest, leading quantitative equity research, intraday trading setups, and derivatives strategy. With 4+ years of experience in Indian equity markets, he combines rigorous quantitative methods with classical technical analysis to build high-conviction research frameworks for retail and advisory clients. He holds an MSc from the Indian Institute of Technology (IIT) Delhi — one of India's most selective institutions — and has completed the Certificate in Quantitative Finance (CQF), a globally recognised programme covering derivatives pricing, risk modelling, machine learning for finance, and advanced portfolio theory. This combination places him in a small group of Indian analysts with both deep academic training in quantitative methods and SEBI-recognised research credentials. Kunal holds seven SEBI-recognised NISM certifications spanning research, derivatives, portfolio management, and securities operations: Series-XV (Research Analyst), Series-XXI-A (Portfolio Managers), Series-XVI (Commodity Derivatives), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-V-A (Mutual Fund Distributors), and Series-I (Currency Derivatives). At Univest — India's SEBI-registered research and advisory platform — Kunal leads research inputs for Pro Lite, Pro Super, Pro Gold, and Pro Commodity advisory services, alongside publishing intraday stock picks on Univest Blogs.

Leave a Reply Cancel reply